Syntara Ltd - Asset Resilience Ratio
Syntara Ltd (SNT) has an Asset Resilience Ratio of 85.55% as of June 2005. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SNT working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2023)
This chart shows how Syntara Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SNT asset base.
Liquid Assets Composition Over Time
This chart breaks down Syntara Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Syntara Ltd for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$32.45 Million | 85.55% |
| Total Liquid Assets | AU$32.45 Million | 85.55% |
Asset Resilience Insights
- Very High Liquidity: Syntara Ltd maintains exceptional liquid asset reserves at 85.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Syntara Ltd Industry Peers by Asset Resilience Ratio
Compare Syntara Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Syntara Ltd (2005–2023)
The table below shows the annual Asset Resilience Ratio data for Syntara Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 36.40% | AU$8.75 Million ≈ $6.19 Million |
AU$24.03 Million ≈ $17.00 Million |
+2.67pp |
| 2022-06-30 | 33.73% | AU$8.49 Million ≈ $6.01 Million |
AU$25.19 Million ≈ $17.82 Million |
-51.82pp |
| 2005-06-30 | 85.55% | AU$32.45 Million ≈ $22.96 Million |
AU$37.94 Million ≈ $26.84 Million |
-- |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more